ChemGenex to begin trial on fix for Gleevec resistance

Australia's ChemGenex said it soon will begin a Phase II trial on its cancer drug, ceflatonin, for treating advanced cancer patients resistant to Gleevec, the only treatment available for chronic myelogenous leukemia. The drug completed Phase II trials about five years ago, but Novartis' Gleevec beat it to market before the resistance was discovered.

View Full Article in:

Herald Sun (Melbourne, Australia) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC